Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 10/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | RHOC | P08134 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22534418 | 0.89 | RHOA (0.65) | RHOAALDH1A1POLBPTPN2PTPN1 | |
| SCHEMBL17805428 | 0.85 | RHOA (0.65) | RHOAALDH1A1POLBRAB9A | |
| SCHEMBL12060563 | 0.85 | ALDH1A1 (0.60) | RHOAALDH1A1POLBHPGDLMNA | |
| SCHEMBL192930 | 0.84 | ALDH1A1 (0.69) | RHOAALDH1A1POLBPTPN1HPGD | |
| SCHEMBL23086155 | 0.83 | PTPN1 (0.86) | ALDH1A1PTPN2PTPN1LMNA | |
| SCHEMBL1520334 | 0.83 | ALDH1A1 (0.64) | ALDH1A1POLBHPGDSMN1; SMN2 | |
| SCHEMBL7232912 | 0.83 | ALDH1A1 (0.64) | ALDH1A1POLBHPGDSMN1; SMN2 | |
| SCHEMBL16442058 | 0.83 | ALDH1A1 (0.64) | ALDH1A1POLBHPGDSMN1; SMN2 | |
| SCHEMBL486205 | 0.83 | KMT2A (0.65) | RHOAPOLBHPGDLMNARAB9A | |
| SCHEMBL19002751 | 0.82 | PKM (0.63) | ALDH1A1HPGDLMNATP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | ARTAX BIOPHARMA INC. | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131125-A1 | ARYL-PIPERIDINE DERIVATIVES | CD4, CD2, CCR1 | RHOA 3949/4885ALDH1A1 1450/4885POLB 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.